Related Experiment Video

Updated: Aug 15, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

[Immunosuppressive therapy of inflammatory diseases of the large intestine]

V G Rumiantsev, V A Rogozina, V A Osina

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |November 2, 2005
    PubMed

    The treatment of ulcerous colitis and Crohn's disease is based on suppression of various components of the immunoinflammatory cascade. In addition to aminosalicylates and glucocorticoids, drugs of primary immunosuppressive action are used for this purpose, which are adopted from clinical oncology and transplantation medicine: azathioprine, 6-mercaptopurine, methotrexate, cyclosporine A, tacrolimus, mycophenolate mofetil, thalidomide. Some of them are used for remission induction in case of hormonal dependence or resistance, while others are applied for its maintenance or at various stages of the inflammatory process course. The presented review discloses problems of clinical pharmacology of immunosuppressive drugs, side effects, results of pilot and clinical studies of ulcerous colitis and Crohn's disease. All this makes it possible to determine their role in the therapy of inflammatory diseases of the bowels.

    More Related Videos

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

    Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

    Published on: April 6, 2022

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

    Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

    Published on: January 5, 2017

    Related Concept Videos

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

    Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

    Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

    Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

    Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    Inflammatory Bowel Disease V: Surgical Management01:21

    Inflammatory Bowel Disease V: Surgical Management

    Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
    Here are some common surgical interventions for IBD: